文献速递特殊人群用药药物不良反应与药物警戒

中枢神经系统药物研发中的意外妊娠与哺乳数据管理现状

Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?: Maintaining the Gap: Pregnancy and Breastfeeding in CNS Clinical Trials.
PubMed 文献 · Clin Pharmacol Ther · 2026-10-22

本研究回顾欧洲药品管理局2012至2022年间35份中枢神经系统产品上市许可申请,评估意外妊娠与哺乳数据的报告与管理情况。共识别451例妊娠,其中343例暴露于研究药物,关键III期试验中108例暴露妊娠有27%结局未知或进行中。仅1份档案含专门的人体哺乳研究,监管机构提出19项妊娠相关和6项哺乳相关关注。

要点

  • 关键III期试验中27%的研究药物暴露妊娠结局未知或进行中,随访不完整。
  • 仅1份上市许可申请档案包含专门的人体哺乳研究,哺乳数据严重缺乏。
  • 妊娠报告在位置、格式和个案细节上差异大,需更结构化的报告与随访。

核心结论

  • 中枢神经系统药物研发中意外妊娠与哺乳数据报告不一致且随访不完整,存在证据缺口。
  • 更结构化的报告与随访,包括暴露和药代动力学数据,可强化临床药理学与监管证据。

研究设计与样本

  • 回顾性审查2012至2022年提交欧洲药品管理局的35份中枢神经系统产品集中授权上市许可申请档案。
  • 从上市许可申请档案、第120天问题清单和产品特征摘要中提取妊娠频率、研究药物暴露、妊娠结局、哺乳数据及监管意见。

主要发现

  • 共识别451例妊娠,其中343例有研究药物暴露。
  • 关键III期试验中108例研究药物暴露妊娠,含39例活产、23例选择性终止、17例自然流产、29例结局未知或进行中。
  • 评估时27%的关键试验研究药物暴露妊娠结局未知或进行中。
  • 监管机构提出19项妊娠相关关注和6项哺乳相关关注。
  • 仅1份档案包含专门的人体哺乳研究。

关键数值与推荐

  • 妊娠报告在位置、格式和个案细节上差异显著。
  • 仅1份上市许可申请档案含专门人体哺乳研究,其余无专门哺乳研究。

临床怎么用

  • 对育龄女性使用中枢神经系统药物时,应关注妊娠暴露后的前瞻性随访与结局记录。
  • 在可行情况下收集妊娠暴露相关药代动力学数据,以支持剂量与安全性评估。
  • 推动哺乳期数据系统化收集,弥补产品信息中哺乳证据不足。

局限性

  • 仅纳入2012至2022年欧洲药品管理局集中授权的35份中枢神经系统产品上市许可申请,未覆盖其他地区或非集中授权产品。
  • 数据来自档案回顾,妊娠结局未知或进行中比例较高,可能影响结局评估完整性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pregnant and breastfeeding individuals are routinely excluded from clinical drug development, creating persistent evidence gaps in pharmacology, safety, and dosing. Despite mandatory contraception and pregnancy testing, unintended pregnancies occur, particularly during the development of central nervous system (CNS) medicines used by women of reproductive age. Once exposure to an investigational medicinal product (IMP) has occurred, these pregnancies may provide valuable prospective human data; however, treatment or trial participation is often discontinued and follow-up may be incomplete. This study assessed how unintended pregnancies and breastfeeding data were reported, managed, and evaluated in clinical trials supporting marketing authorization applications (MAAs) for CNS products. We reviewed 35 MAAs for centrally authorized CNS products submitted to the European Medicines Agency between 2012 and 2022. Pregnancy frequency, IMP exposure, pregnancy outcomes, breastfeeding data and regulatory comments were extracted from MAA dossiers, Day 120 Lists of Questions and Summaries of Product Characteristics. Overall, 451 pregnancies were identified, including 343 with IMP exposure. Of these, 108 occurred in pivotal phase 3 trials, resulting in 39 live births, 23 elective terminations, 17 spontaneous pregnancy losses, and 29 unknown or ongoing outcomes. Regulators raised 19 pregnancy-related and six breastfeeding-related concerns. Only one dossier included a dedicated human lactation study. Pregnancy reporting varied substantially in location, format and case-level detail, while 27% of pivotal IMP-exposed pregnancies had unknown or ongoing outcomes at assessment. More structured reporting and follow-up, including relevant exposure and pharmacokinetic data where feasible, could strengthen clinical pharmacology and regulatory evidence and support more informative product information.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Schoenmakers S, Bakker C, Ganev A, et al. Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?: Maintaining the Gap: Pregnancy and Breastfeeding in CNS Clinical Trials. Clin Pharmacol Ther. 2026. PMID: 42910662. doi:10.1002/cpt.70529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。